Li H, et al. - In advanced lung adenocarcinoma patients with uncommon epithelial growth factor receptor (EGFR) mutations, the outcomes of first-line treatment with first generation EGFR tyrosine kinase inhibitors (EGFR-TKI) or platinum-based chemotherapy were assessed, focusing on long-term survival. Overall 4,276 advanced (IIIB/IV) patients were included and were examined for the presence of EGFR gene. Those having uncommon EGFR mutations were assessed taking into account clinic features, survival outcomes data, treatment outcomes and data of subsequent therapies after first-line treatment and were compared with common EGFR mutations. The short-term efficacy of advanced lung adenocarcinoma patients with uncommon EGFR mutations could be improved with first-line treatment with first generation EGFR-TKIs vs chemotherapy, but longer overall survival was offered by platinum-based chemotherapy. In these patients, independent prognostic factors for overall survival were extra metastases and smoking history.